Piersen C E, True C D, Wells J N
Department of Pharmacology, Vanderbilt University School of Medicine, Nashville, Tennessee 37232-6600.
Mol Pharmacol. 1994 May;45(5):871-7.
We have shown previously that 125I-2-[4-[2-[2-[(4-azidophenyl)methylcarbonylamino] ethylaminocarbonyl]ethyl]phenyl] ethylamino-5'-N-ethylcarboxamidoadenosine (125I-azido-PAPA-APEC) specifically and selectively photolabels RDC8 A2a adenosine receptors that have been overexpressed in COS M6 cells. Glycosylated, 125I-azido-PAPA-APEC-labeled, wild-type (412 residues; 45,031 Da) and carboxyl-terminally truncated (315 residues; 35,427 Da) receptors migrate with apparent molecular masses of > 40 and 31.5 kDa, respectively, whereas unglycosylated or deglycosylated wild-type and truncated A2a receptors migrate with apparent molecular masses of 40 and 28.5 kDa, respectively. Because nonspecific photoincorporation is not a complication, the present peptide mapping studies of the full length and truncated canine A2a adenosine receptors were carried out on unpurified COS M6 membrane preparations. After partial proteolysis it became clear that glycosylation increased the apparent molecular mass of either the wild-type or mutant A2a receptor by approximately 3 kDa. Although the A2a receptor was readily cleaved by a variety of chemical reagents and proteases, trypsin and endoproteinase Glu-C generated the most reproducible and, in the case of trypsin, the most complete fragmentation patterns. Radiolabeled peptides were identified by their apparent molecular masses, (in)abilities to be recognized by an antipeptide antibody to amino acids Tyr155-Val172 of the presumed second extracellular loop of the receptor, and (in)sensitivities to endoglycosidase F and tunicamycin treatments. A prominent, 7-kDa, radiolabeled peptide that was generated by trypsin digestion implicated putative alpha-helix V in the binding of 125I-azido-PAPA-APEC.
我们之前已经表明,125I-2-[4-[2-[2-[(4-叠氮基苯基)甲基羰基氨基]乙基氨基羰基]乙基]苯基]乙基氨基-5'-N-乙基羧酰胺基腺苷(125I-叠氮基-PAPA-APEC)能特异性且选择性地光标记在COS M6细胞中过表达的RDC8 A2a腺苷受体。糖基化的、125I-叠氮基-PAPA-APEC标记的野生型(412个残基;45,031 Da)和羧基末端截短型(315个残基;35,427 Da)受体的表观分子量分别大于40 kDa和31.5 kDa,而未糖基化或去糖基化的野生型和截短型A2a受体的表观分子量分别为40 kDa和28.5 kDa。由于非特异性光掺入不是一个复杂问题,因此对未纯化的COS M6膜制剂进行了全长及截短型犬A2a腺苷受体的肽图谱研究。部分蛋白酶解后发现,糖基化使野生型或突变型A2a受体的表观分子量增加了约3 kDa。尽管A2a受体很容易被多种化学试剂和蛋白酶切割,但胰蛋白酶和内肽酶Glu-C产生的片段模式最具重复性,就胰蛋白酶而言,产生的片段模式也最完整。通过其表观分子量、是否能被针对受体假定的第二个细胞外环中氨基酸Tyr155-Val172的抗肽抗体识别以及对内切糖苷酶F和衣霉素处理的敏感性来鉴定放射性标记的肽。胰蛋白酶消化产生的一个突出的7 kDa放射性标记肽表明,假定的α-螺旋V参与了125I-叠氮基-PAPA-APEC的结合。